Covidien to Acquire Oridion Systems for $346 Million
Covidien will pay about 21.04 Swiss francs ($23) a Oridion share, 75 percent higher than yesterday’s closing stock price. The merger is expected to be completed in the second quarter, according to a statement.
The acquisition of Jerusalem-based Oridion, a maker of devices for patient breathing safety, is intended to add to Covidien’s portfolio of devices to monitor “respiratory function for patients around the world,” Robert J. White, president of Respiratory & Monitoring Systems at Covidien, said in the statement. Oridion had $64.5 million of revenue in 2011.
Covidien doesn’t expect the transaction to have a material effect on its fiscal 2012 sales, operating margin or earnings per share, the Dublin-based company said in the statement. The boards of both companies have approved the deal, which is is subject to Oridion shareholders’ approval, Covidien and Oridion said.
To contact the editor responsible for this story: Phil Serafino at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.